This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Implant Sales Plump Up Mentor

Sales of Mentor's (MNT) silicone MemoryGel implants provided a lift to the company's fiscal first-quarter results and shares Tuesday.

Excluding the results of discontinued operations of the company's urology business, Mentor reported earning 48 cents a diluted share in the first quarter of fiscal 2008, compared to 33 cents a share in the prior-year quarter -- a 45% increase.

Analysts polled by Thomson Financial had expected 34 cents a share on revenue of $88.4 million.

Net sales rose 20% to $95.6 million compared to $79.4 million in the year-ago quarter. Mentor said the boost in net sales was primarily due to strong sales of its MemoryGel breast implants in the U.S. augmentation market, which Mentor said is transitioning from saline-filled breast implants to silicone breast implants.

After the close of the quarter, the company announced it was purchasing all of the outstanding shares of Perouse Plastie SAS, a French breast implant company, for about $56.5 million.

"From a strategic standpoint, the acquisition of Perouse Plastie at the end of the quarter expands the company's international product offerings and positions Mentor for future growth and expansion in key international markets," said CEO Joshua Levine.

Looking ahead, with that acquisition accounted for, the company expects fiscal 2008 sales to range from $370 million to $385 million for the year and operating income to be about 20% of sales. It expects to earn $1.40 to $1.45 a diluted share from continuing operations.

In reaction to the strong quarterly results, Piper Jaffray upgraded Mentor's stock rating from underperform to market perform with a $45 price target.

Mentor gained $5.76, or 14.5%, to $46.75 in recent trading Tuesday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $118.63 0.28%
FB $105.37 1.10%
GOOG $758.82 2.20%
TSLA $235.40 2.20%
YHOO $33.66 -0.44%


Chart of I:DJI
DOW 17,890.83 +170.91 0.96%
S&P 500 2,094.40 +13.99 0.67%
NASDAQ 5,134.48 +25.8140 0.51%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs